Healthcare - Solomon Grey Capital

A pharmaceutical manufacturing line with stainless steel vessels and blue rim lighting

Research

The $500 Billion U.S. Drug Factory: Why Tariff-Driven Pharma Capex Is a Margin Trade, Not a Manufacturing Boom

Drugmakers are pledging $500 billion for U.S. capacity. The contrarian read: this is a margin and tariff-avoidance trade, not proof every plant will pay back.

Research

Novo's Better Forecast: Why a Higher 2026 Guide Cannot Repair the Obesity Franchise

Novo Nordisk raised its 2026 outlook, but investors sold the stock. The market is pricing a pipeline gap, not disputing one quarter's execution.

A chrome laboratory microscope on dark marble lit by warm amber light — Solomon Grey Capital editorial illustration for the Merck KGaA Bio-Techne $11.3 billion life sciences tools deal.

Healthcare

The Life Sciences Tools Re-Rating: Why Merck KGaA's $11.3 Billion Bid Just Reset a Sub-Sector the Public Market Wrote Off

Merck KGaA's $11.3 billion cash bid for Bio-Techne is not another pharma M&A headline. At 10x sales for a research tools platform, it is a strategic admission that the sub-sector cycle has bottomed and the multiples have over-corrected. The implications run well past one deal.

Research

GSK's $10.6 Billion Nashville: Why the Nuvalent Multiple Just Reset the Patent-Cliff Math for Every Major Drugmaker

John Grey — Healthcare & longevity desk On the morning the markets were busy pricing a US-Iran ceasefire and a Federal Reserve hold, GSK’s new chief executive wrote the largest cheque of his tenure for a Cambridge, Massachusetts biotech that has yet to generate a single dollar of commercial

An empty pharmaceutical laboratory at dusk with a polished stainless steel bench, a single glass beaker holding clear liquid, soft amber light from an overhead pendant fixture

Research

Citi's Six-Stock SMid Biotech Note: Why the Buy-Buy-Buy-Buy-Buy-Neutral Pattern Is the Sector Inflection

Citi initiated coverage on six SMid biotechs last Monday. Five Buys. One Neutral. The pattern, not the targets, is the sector call long-only generalists missed.

An unmarked amber prescription pill bottle on a polished dark desk with a single warm gold beam of light cutting horizontally across the surface like a balance-sheet line

Research

The GLP-1 Bridge Nobody Wanted to Underwrite: Why Medicare's $50 Copay Is a Fiscal Event, Not a Pharma One

Medicare will cover GLP-1s for obesity from July 1. Private insurers refused the BALANCE risk and CMS took it on alone. The biotechs got the easy read. The fiscal arithmetic is the harder one.